SUBSCRIBERS
Valeant investors doubting drugmaker's chief can regain grip
The company is in worse shape after Michael Pearson returned from a two-month medical leave for pneumonia
Published Wed, Mar 16, 2016 · 09:50 PM
'%3e%3cpath%20d='M20.7725%2026.9924C20.9555%2026.9924%2021.1297%2026.953%2021.2951%2026.8741C21.4604%2026.7953%2021.6346%2026.6694%2021.8177%2026.4965L27.8373%2020.8125C27.9848%2020.6752%2028.0865%2020.5353%2028.1425%2020.3929C28.1985%2020.2505%2028.2264%2020.1183%2028.2264%2019.9962C28.2264%2019.869%2028.1985%2019.7343%2028.1425%2019.5918C28.0865%2019.4494%2027.9848%2019.3095%2027.8373%2019.1722L21.8177%2013.5417C21.6142%2013.3484%2021.4375%2013.2098%2021.2875%2013.1259C21.1374%2013.042%2020.9708%2013%2020.7877%2013C20.5181%2013%2020.2981%2013.0916%2020.1278%2013.2747C19.9574%2013.4578%2019.8722%2013.6765%2019.8722%2013.9308V16.8147H19.6509C18.2827%2016.8147%2017.1014%2017.0258%2016.107%2017.448C15.1127%2017.8701%2014.2963%2018.4805%2013.658%2019.279C13.0197%2020.0776%2012.5466%2021.0402%2012.2389%2022.1668C11.9312%2023.2934%2011.7773%2024.5612%2011.7773%2025.9701C11.7773%2026.3006%2011.8575%2026.5537%2012.0177%2026.7291C12.1779%2026.9047%2012.3597%2026.9924%2012.5632%2026.9924C12.7259%2026.9924%2012.89%2026.9593%2013.0553%2026.8932C13.2206%2026.8271%2013.3693%2026.6719%2013.5016%2026.4278C13.9441%2025.5936%2014.4553%2024.9413%2015.0351%2024.4708C15.6149%2024.0004%2016.2838%2023.6685%2017.0417%2023.4752C17.7995%2023.2819%2018.6693%2023.1853%2019.6509%2023.1853H19.8722V26.0998C19.8722%2026.3591%2019.9574%2026.5728%2020.1278%2026.7406C20.2981%2026.9085%2020.513%2026.9924%2020.7725%2026.9924Z'%20fill='black'%20fill-opacity='0.85'/%3e%3c/g%3e%3crect%20x='0.5'%20y='0.5'%20width='39'%20height='39'%20rx='19.5'%20stroke='%23F2F2F2'/%3e%3cdefs%3e%3cclipPath%20id='clip0_715_28555'%3e%3crect%20width='16.4491'%20height='14'%20fill='white'%20transform='translate(11.7773%2013)'/%3e%3c/clipPath%3e%3c/defs%3e%3c/svg%3e){kind=small}
Boston
MICHAEL Pearson and his company, Valeant Pharmaceuticals International Inc, were supposed to calm Wall Street doubters on Tuesday. Instead: chaos.
What began before dawn with disappointing financial news quickly snowballed into the worst day in the drug company's history, leaving investors wondering if Mr Pearson, its controversial chief, can regain his grip.
'/%3e%3cpath%20d='M35.1847%2014.0422L9.37867%2024.1703C8.88772%2024.363%208.86989%2025.051%209.35015%2025.2688L15.0551%2027.8567C15.2097%2027.9269%2015.327%2028.0594%2015.3778%2028.2212L17.8255%2036.0078C17.9491%2036.4009%2018.4247%2036.5534%2018.7539%2036.3054L23.0143%2033.0968C23.2178%2032.9435%2023.4961%2032.9364%2023.7072%2033.0787L30.8526%2037.8975C31.2091%2038.1378%2031.6951%2037.9339%2031.7732%2037.5114L35.9896%2014.7059C36.0747%2014.2456%2035.6206%2013.8712%2035.1847%2014.0422Z'%20fill='%23FDFEFF'/%3e%3cpath%20d='M15.3125%2027.9998L30.4162%2018.627L19.3691%2029.3628L19.548%2033.3966L18.9531%2036.1248C18.3783%2036.7236%2017.9297%2036.2772%2017.8477%2036.0662L15.3681%2028.178L15.2734%2028.0233L15.3125%2027.9998Z'%20fill='%23C8DAEA'/%3e%3cpath%20d='M18.3594%2036.4259L19.3511%2029.3447L23.519%2032.9856C23.303%2032.9612%2023.1588%2032.9863%2023.0268%2033.0859L19.0712%2036.0718C18.6289%2036.4572%2018.4297%2036.4455%2018.3594%2036.4259Z'%20fill='%23A9C9DD'/%3e%3cdefs%3e%3clinearGradient%20id='paint0_linear'%20x1='33'%20y1='7.5'%20x2='19'%20y2='36.5'%20gradientUnits='userSpaceOnUse'%3e%3cstop%20stop-color='%231E96C8'/%3e%3cstop%20offset='1'%20stop-color='%2337AEE2'%20stop-opacity='0'/%3e%3c/linearGradient%3e%3c/defs%3e%3c/svg%3e)
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
IndoAgri appoints former EDB chairman Philip Yeo as chairman and lead independent director
GSK profit drops 23% in Q1 on higher costs
Starbucks points to weaker consumer as profit falls
Restaurant Brands tops estimates as Burger King overhaul pays off
Walmart to shut all health centers in US over lack of profitability
Coca-Cola raises annual sales forecast on global demand, higher prices
